MARKET

DCTH

DCTH

Delcath Sys
NASDAQ
10.02
+0.36
+3.73%
After Hours: 10.12 +0.1 +1.00% 19:29 12/04 EST
OPEN
9.67
PREV CLOSE
9.66
HIGH
10.12
LOW
9.57
VOLUME
605.99K
TURNOVER
--
52 WEEK HIGH
18.23
52 WEEK LOW
8.12
MARKET CAP
353.84M
P/E (TTM)
1151.72
1D
5D
1M
3M
1Y
5Y
1D
Analysts Offer Insights on Healthcare Companies: Delcath Systems (DCTH) and Champions Oncology (CSBR)
TipRanks · 16h ago
Delcath Systems 10-Year Data From Retrospective Study On Patients With Liver-Dominant Metastatic Uveal Melanoma Shows Safety, Efficacy Of CHEMOSAT
Benzinga · 1d ago
Delcath Systems announces publication of CHEMOSAT study
TipRanks · 1d ago
Delcath Systems Reports 10-Year Study Showing Improved Survival With Hepatic Perfusion in Metastatic Uveal Melanoma
Reuters · 1d ago
Stephens Reaffirms Their Buy Rating on Delcath Systems (DCTH)
TipRanks · 1d ago
Weekly Report: what happened at DCTH last week (1124-1128)?
Weekly Report · 3d ago
Delcath Systems Director John Richard Sylvester Reports Acquisition of Common Shares
Reuters · 11/25 21:16
Weekly Report: what happened at DCTH last week (1117-1121)?
Weekly Report · 11/24 09:17
More
About DCTH
Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. The Company's proprietary products, HEPZATO KIT (HEPZATO (melphalan) for Injection/Hepatic Delivery System) and CHEMOSAT Hepatic Delivery System for Melphalan percutaneous hepatic perfusion (PHP), are designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects during a PHP procedure. HEPZATOTM KIT is a drug/device combination product. HEPZATO KIT is comprised of the chemotherapeutic drug melphalan and the Company’s proprietary Hepatic Delivery System (HDS). In Europe, the device-only configuration of the HDS is regulated as a Class III medical device and is approved for sale under the trade name CHEMOSAT Hepatic Delivery System for Melphalan. In the United States, HEPZATO is regulated as a drug by the United States Food and Drug Administration (FDA).

Webull offers Delcath Systems Inc stock information, including NASDAQ: DCTH real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, DCTH stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading DCTH stock methods without spending real money on the virtual paper trading platform.